AIM: To describe the rationale and design of a pilot program to implement and evaluate pharmacogenetic (PGx) testing in a primary care setting. STUDY RATIONALE: Several factors have impeded the uptake of PGx testing, including lack of provider knowledge and challenges with operationalizing PGx testing in a clinical practice setting. STUDY DESIGN: We plan to compare two strategies for the implementation of PGx testing: a pharmacist-initiated testing arm compared with a physician-initiated PGx testing arm. Providers in both groups will be required to attend an introduction to PGx seminar. Anticipated results: We anticipate that providers in the pharmacist-initiated group will be more likely to order PGx testing than providers in the physician-initiated group. CONCLUSION: Overall, we aim to generate data that will inform an effective delivery model for PGx testing and to facilitate a seamless integration of PGx testing in primary care practices.
AIM: To describe the rationale and design of a pilot program to implement and evaluate pharmacogenetic (PGx) testing in a primary care setting. STUDY RATIONALE: Several factors have impeded the uptake of PGx testing, including lack of provider knowledge and challenges with operationalizing PGx testing in a clinical practice setting. STUDY DESIGN: We plan to compare two strategies for the implementation of PGx testing: a pharmacist-initiated testing arm compared with a physician-initiated PGx testing arm. Providers in both groups will be required to attend an introduction to PGx seminar. Anticipated results: We anticipate that providers in the pharmacist-initiated group will be more likely to order PGx testing than providers in the physician-initiated group. CONCLUSION: Overall, we aim to generate data that will inform an effective delivery model for PGx testing and to facilitate a seamless integration of PGx testing in primary care practices.
Entities:
Keywords:
clinical utility; pharmacist support; pharmacogenetic testing; pharmacogenetics; primary care
Authors: Olga A Iakoubova; Carmen H Tong; Charles M Rowland; Todd G Kirchgessner; Bradford A Young; Andre R Arellano; Dov Shiffman; Marc S Sabatine; Hannia Campos; Christopher J Packard; Marc A Pfeffer; Thomas J White; Eugene Braunwald; James Shepherd; James J Devlin; Frank M Sacks Journal: J Am Coll Cardiol Date: 2008-01-29 Impact factor: 24.094
Authors: Gilberto de Lima Lopes; Joel E Segel; Daniel S W Tan; Young K Do; Tony Mok; Eric A Finkelstein Journal: Cancer Date: 2011-07-26 Impact factor: 6.860
Authors: Melanie E Ziman; Hien T Bui; Craig S Smith; Lori A Tsukiji; Veda M Asmatey; Steven B Chu; John S Miano Journal: J Pharm Pract Date: 2011-08-15
Authors: Elisa Jf Houwink; Scheltus J van Luijk; Lidewij Henneman; Cees van der Vleuten; Geert Jan Dinant; Martina C Cornel Journal: BMC Fam Pract Date: 2011-02-17 Impact factor: 2.497
Authors: Elisa J F Houwink; Arno M M Muijtjens; Sarah R van Teeffelen; Lidewij Henneman; Jan Joost Rethans; Liesbeth E J van der Jagt; Scheltus J van Luijk; Geert Jan Dinant; Cees van der Vleuten; Martina C Cornel Journal: Genet Med Date: 2013-05-30 Impact factor: 8.822
Authors: Martin Dawes; Martin N Aloise; J Sidney Ang; Pieter Cullis; Diana Dawes; Robert Fraser; Gideon Liknaitzky; Andrea Paterson; Paul Stanley; Adriana Suarez-Gonzalez; Hagit Katzov-Eckert Journal: CMAJ Open Date: 2016-09-21
Authors: Jason L Vassy; Sojeong Chun; Sanjay Advani; Sophie A Ludin; Jason G Smith; Elaine C Alligood Journal: Clin Pharmacol Ther Date: 2018-10-18 Impact factor: 6.875
Authors: S Harada; Y Zhou; S Duncan; A R Armstead; G M Coshatt; C Dillon; B C Brott; J Willig; J A Alsip; W B Hillegass; N A Limdi Journal: Clin Pharmacol Ther Date: 2017-06-01 Impact factor: 6.875
Authors: Tien M Truong; Jeffrey L Apfelbaum; Emily Schierer; Keith Danahey; Brittany A Borden; Theodore Karrison; Sajid Shahul; Magdalena Anitescu; Rebecca Gerlach; Randall W Knoebel; David O Meltzer; Mark J Ratain; Peter H O'Donnell Journal: Pharmacogenet Genomics Date: 2022-04-01 Impact factor: 2.089